Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia

Journal of Investigative Medicine

Volumn 47, Issue 8, 1999, Pages 378-387

  Streicher, Johannes ^a   Valent, Peter ^a   Schmidt, Helena ^a   Sengölge, Gürkan ^a   Wagner, Oswald ^a   Strobl, Wolfgang ^a   Hörl, Walter H ^a   Derfler, Kurt ^a  

^a Department of Anatomy ^*

Author keywords

Flow cytometry; LDL apheresis; LDL cholesterol; LDL receptor

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; ANTIBODY COMBINING SITE; APHERESIS; ARTICLE; BLOOD; CELL CULTURE; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL; UPREGULATION;

ADULT; BINDING SITES, ANTIBODY; BLOOD COMPONENT REMOVAL; CELLS, CULTURED; CHOLESTEROL, LDL; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; IMMUNOSORBENT TECHNIQUES; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, LDL; UP-REGULATION;

EID: 0033193317     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Breslow JL. Genetics of lipoprotein disorders. Circulation 1993;87(III Suppl):16-21.
2. Goldstein JL, Hobbs HH, MS Brown. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. Vol. 2. New York, NY: McGraw-Hill, 1995:1981-2030.
3. Grundy SM, Vega GL. Causes of high blood cholesterol. Circulation 1990;81:412-27.
4. Kontula K, Ehnholm C. Regulatory mutations in human lipoprotein disorders and atherosclerosis. Curr Opin Lipidol 1996;7(2):64-8.
5. Krass RM, Kesäniemi YA. Cardiovascular disease and hyperlipidaemia: editorial comment. Curr Opin Lipidol 1994;5:249-51.
6. Pitas RE, Friera A, McGuire J, Dejager S. Further characterization of the acethyl LDL (scavenger) receptor expressed by rabbit smooth muscle cells and fibroblasts. ArteriosclerThromb 1992;12(11):1235-44.
7. Kroon AA, van Asten WNJC, Stalenhoef AFH. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996;125:945-54.
8. Kroon AA, Aengevaeren WRW, van der Werf T, Uijen GJH, Reiber JHC, Bruschke AVG, Stalenhoef AFM. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
9. Richter WO, Jacob BG, Ritter MM, Sühler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 1993;42:888-94.
10. Tikkanen MJ. Stalins: within-group comparisons, statin escape and combination therapy. Curr Opin Lipidol 1996;7(6):385-8.
11. Watts GF, Burke V. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol 1996;7:341-55.
12. Sacks FM, Pfeffer MA, Lemuel AM, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9.
13. Jansen M, Gabriel H, Banyai S, Pidlich J, Weidinger F, Hörl WH, Derfler K. Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient. Wien Klin Wochenschr 1996;108(14):425-31.
14. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336(5):332-6.
15. Gordon BR, Saal SD. Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia. Curr Opin Lipidol 1996;7(6):381-4.
16. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 1992;95:1-13.
17. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, et al. Familial hypercholesterolaemia regression study: a randomized trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-6.
18. Swoboda K, Derfler K, Koppensteiner R, Langer M, Pamberger P, Ehringer H, Druml W, Widhalm K. Extracorporeal lipid elimination for treatment of gestational hyperlipidemic pancreatitis. Gastroenterology 1993;104:1527-31.
19. Schmitz G, Brüning T, Kovacs E, Barlage S. Fluorescence flow cytometry of human leukocytes in the detection of LDL receptor defects in the differential diagnosis of hypercholesterolemia. Arteriosclerosis and Thrombosis 1993;13:1053-65.
20. Rudling M, Angelin B. Stimulation of rat hepatic low density lipoprotein receptors by glucagon: evidence of a novel regulatory mechanism in vivo. J Clin Invest 1993;91:2796-805.
21. Beisiegel U, Schneider WJ, Goldstein JL, Anderson RGW, Brown MS. Monoclonal antibodies to the low density lipoprotein receptor as probes for study of receptor-mediated endocytosis and the genetics of familial hypercholesterolemia. J Biol Chem 1981;256:11923-31.
22. Derfler K, Swoboda K, Hirschl MM, Gottsauner-Wolf M, Steger G, Sunder-Plassmann G, Widhalm K. Comparison of plasma separation and immunospecific LDL-elimination in severe hypercholesterolemia. Int J Artif Organs 1992;15:307-8.
23. Derfler K. Long-term low-density lipoprotein immunoapheresis in renal disease. In: Keane WF, Hörl WH, Kasiske BL, eds. Lipids and the kidney. Vol. 120. Basel, Switzerland: Karger, 1997:105-19.
24. Du Moulin A. LDL immunapheresis technique. Basel, Switzerland: Karger, 1990:170-4.
25. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
26. Südhof TC, Goldstein JL, Brown MS, Russell DW. The LDL receptor gene: a mosaic of exons shared with different proteins. Science 1985;228:815-22.
27. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E binding protein. Nature 1989;341:162-4.
28. Liscum L, Faust JR. Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fibroblasts. J Biol Chem 1997;262:17002-8.
29. Brown MS, Goldstein JL. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell 1975;6:307.
30. Franceschini G, Lovati MR, Manzoni C, Michelagnoli S, Pazzucconi F, Gianfranceschi G, Vecchio G, Sirtori CR. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis 1995;114:61-71.
31. Malle E, Oettl K, Sattler W, Hoefler G, Kostner GM. Cholesterol biosynthesis in dermal fibroblasts from patients with metabolic disorders of peroxisomal origin. Eur J Clin Invest 1995;25:59-67.
32. Raveh D, Israeli A, Arnon R, Eisenberg S. Effects of lovastatin on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins. Atherosclerosis 1990;82:19-26.
33. Roach PD, Hosking J, Clifton PM, Bais R, Kusenic B, Coyle P, Wight MB, Thomas DW, Nestel PJ. The effects of hypercholesterolaemia, simvastatin and dietary fat on the low density lipoprotein receptor of unstimulated mononuclear cells. Atherosclerosis 1993;103:245-54.
34. Qin W, Infante J, Wang S-R, Infante R. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Biochim Biophys Acta 1992;1127:57-66.
35. Gaddi A, Area M, Ciarrocchi A, Fazio S, D'Alò G, Tiozzo R, Descovich GC, Calandra S. Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprtein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts. Metabolism 1991;40(10):1074-8.
36. Reihner E, Rudling M, Stahlberg D, Berglund L, Ewerth S, Björkheim I, Einarsson K, Angelin B. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1991;323:224-8.
37. Stein KA. Drug and alternative therapies for hyperlipidemia. Atherosclerosis 1994; 108(Suppl):105-16.
38. Vega GL, Grundy SM. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidemia. J Intern Med 1991;230:341-9.
39. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 1995;270:19269-76.
40. Shepherd J, Packard CJ, Bicker S, Lawrie TDV, Morgan HG. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 1980;302:1219-22.
41. Pfohl M, Naoumova RP, Klass C, Knisel W, Jakober B, Risler T, Thompson GR. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res 1994;35:1946-55.
42. Kostner KM, Jansen M, Maurer G, Derfler K. LDL-apheresis significantly reduces urinary apo(a) excretion. Eur J Clin Invest 1997;27:93-5.
43. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus and familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990;24:133-70.
44. Davis CG, Goldstein JL, Südhof TC, Anderson RGW, Russell DW, Brown MS. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature 1987;326:760-5.
45. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992;1:445-66.
46. Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest 1990;85:1014-23.
47. Lehrman MA, Schneider WJ, Brown MS, Davis CG, Elhammer A, Russell DW, Goldstein JL. The Lebanese allele at the LDL receptor locus: nonsense mutation produces truncated receptors that is retained in endoplasmic reticulum. J Biol Chem 1987;262:401-10.
48. Brown MS, Anderson RGW, Goldstein JL. Recycling receptors: the round-trip itinerary of migrant membrane proteins. Cell 1983;32:663-7.
49. Basu SK, Goldstein JL, Anderson RGW, Brown MS. Monensin interrupts the recycling of low density lipoprotein receptors in human fibroblasts. Cell 1991;24:493-502.
50. Vuorio AF, Ojala JP, Sarna S, Turtola H, Tikkanen MJ, Kontula K. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. J Intern Med 1995;237:43-8.